COVID-BioB Cohort Study: the neutralizing antibody response to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for virus control and survival

Study population

We studied 162 patients with confirmed SARS-CoV-2 infection enrolled from February 25^th, 2020 in the COVID-19 clinical-biological cohort study (COVID-BioB) at the IRCCS San Raffaele Hospital (ClinicalTrialsgov-NCT04318366) as previously described (Supplementary Materials, SM).¹⁵ Biological material for COVID-BioB included a dedicated serum sample collected at hospital attendance (in-hospital sample) either in the Emergency Department (ED) or the ward and follow-up samples collected in the out-patient clinic at planned 1, 3 and 6 months visits post-discharge. An in-hospital sample was available for 150 patients, while follow-up samples were available for 87 patients at the 1 month visit, 77 patients at the 3 month visit, and 46 patients at the 6 months visit (table 1). Twelve patients with no history of hospital admission were followed at the out-patient clinic for up to five visits.

Fluid-phase luciferase immune precipitation (LIPS) assay

Antibodies were measured by LIPS assays.⁴ We expressed by transient transfection into Expi293F™ cells (Thermo Fisher Scientific, Waltham, MA, USA) several recombinant viral antigens tagged with a Nanoluciferase reporter (Promega, Madison, Wisconsin, USA) as described in SM and figure S2. Each antigen was incubated in liquid phase with test serum (1ul) for 2 h, followed by immune-complexes capture with rProtein A-sepharose and measurement of recovered luciferase activity in a XS960 Centro luminometer (Berthold). Using positive sera as standards, raw data was then converted into arbitrary units (AU).

Lentiviral vector-based SARS-CoV-2 neutralization assay

LV expressing Luciferase (LV-Luc) pseudotyped with a membrane tethered Spike protein, either full length or with a 21 aminoacid truncated cytoplasmic tail (C3), or the VSV.G glycoprotein were produced by transient transfection of 293T Lenti-X cells with transfer vector plasmid pGAE-LucW, packaging plasmid pADSIV3+ and pseudotyping plasmid (pSpike, pSpike-C3 or phCMV-VSV.G) as detailed in SM. LV-Luc preparations were titered on VeroE6 cells and dilutions providing 150,000-200,000 RLU were used in the neutralization assay. Serum serial 3-fold dilutions starting from the 1/40 dilution were incubated in duplicate with the LV-Luc for 30 min at 37°C in 96-well plates, and thereafter added to VeroE6 cells. After 48 h luciferase expression was determined with a luciferase assay system (Bright-Glo, Promega) and measured in a Mitras luminometer (Berthold). Inhibitory serum dilution (ID) 50 was calculated with a linear interpolation method.¹⁶

Statistical analysis

Median with either 95% CI, range, or inter-quartiles range (IQR) in parenthesis and frequency or percent were used to report continuous variables and categorical variables, respectively. Chi-square or Fischer’s exact test were used to compare categorical variables. Wilcoxon rank sum or Kruskal-Wallis test were used to compare continuous variables. Imputation for missing data was not performed. Time-to-event was calculated from the date of symptom onset to the date of death, or of last follow up visit, whichever occurred first. Survival was estimated according to Kaplan–Meier. Association between antibody positivity and time to death was calculated using univariate and multivariate Cox proportional hazards models. The effect was reported as hazard ratio (HR) with the corresponding 95% CI, estimated using the Wald approximation. All survival analysis and association were stratified according to time from the onset of symptoms to blood sampling (weeks 1, 2, 3, ≥ 4). Two-tailed p values are reported, with p value <0.05 indicating statistical significance. All confidence intervals are two-sided and not adjusted for multiple testing. Statistical analyses were performed with SPSS 24 (SPSS Inc./IBM) and the R software version 3.4.3.¹⁷

Role of the funding source

The sponsors had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

COVID-BioB Study Cohort characteristics

We profiled the humoral immune response of 162 patients of our COVID-BioB cohort. All had a confirmed SARS-CoV-2 infection and a record of symptoms onset. Serum samples were collected at hospital admission in March-April and at the out-patient visits during follow-up until Nov 25, 2020 (table 1). Patients were predominantly Caucasian (89.5%), male (66.7%) and had a median age of 63 years. A relevant fraction had a body mass index >30 (32.4%) and 57.4% had one or more co-morbidity, with hypertension (44.4%) and diabetes (24.7%) being the most frequent (table 2). Patients sought an emergency hospital visit after a median of nine days from symptoms onset and 134 were hospitalized. At admission, symptoms consisted prevalently of fever, fatigue and respiratory difficulties often associated with dyspnea. The median hospitalization duration was 14 days. Overall, 26 patients entered the Intensive Care Unit (ICU) and 29 passed away, of whom 11 after ICU entry. The median time to a negative RT-PCR results of the naso-pharyngeal swab was 40 days (IC95% 37-43). Patients who recovered were followed-up for a median of 201 days (range 145-250) from symptom onset. The set of laboratory blood tests recorded as per COVID-BioB protocol is presented in table S1 and SM. The general characteristics of this study cohort reflect those of the overall COVID-19 patients admitted to our hospital during the same period and previously described.^4,15

Truncated Spike on LV pseudovirions improves infectivity and is suitable for SARS-CoV-2 neutralization assay

To test the nAb response, we developed and optimized a Lentiviral (LV)-based SARS-CoV-2 neutralization assay, suitable for handling in a Biosafety Level 2 environment. This assay is based on Luciferase expressing LV (LV-Luc) pseudoparticles, enveloped with a Spike glycoprotein containing a 21aa deletion in the cytoplasmic tail (Spike-C3) (SM, figure S1). This truncation removes an endoplasmic reticulum (ER) retention signal that interferes with the budding of viral particles,^18,19 thus favoring the interaction of Spike and Gag proteins during particle assembly.²⁰ Upon transfection into 293T Lenti-X cells of either full-length Spike or Spike-C3 expression plasmids, both constructs showed comparable expression levels on the cell surface (figure 1A). Conversely Spike-C3 was incorporated on the pseudoparticles’ surface at higher levels than the whole Spike, though Gag protein content was comparable across all preparations (figure 1B).

• Download figure
• Open in new tab

Figure 1: Higher incorporation of truncated Spike on LV pseudovirions improves infectivity in ACE2+ cell lines.

(A) Evaluation of SARS-CoV-2 Spike expression in 293T Lenti-X cells transfected with pSpike and pSpike-C3 plasmid by flow cytometry. (B) Western blot (WB) of lysates from concentrated preparations of LV-Luc pseudotyped with wild type Spike (LV-Luc/Spike) or Spike truncated (21aa) at the cytoplasmic tail (LV-Luc/Spike-C3). Low dose: 1×10⁵ RT units; High dose: 6×10⁵ reverse transcriptase (RT) Units. Control vector included LV-Luc pseudotyped with VSV.G envelope (LV-Luc/VSV.G). (C) Infection of human and macaque epithelial cell lines and the control B cell line Raji incubated with decreasing concentrations of LV-Luc pseudotyping the full length (LV-Luc/Spike) or the truncated form (LV-Luc/Spike-C3) of the SARS-CoV-2 Spike. Data are expressed as mean luciferase activity (RLU, Relative Light Units) of duplicates.

LV-Luc/Spike and LV-Luc/Spike-C3 infectivity was tested in a panel of human and macaque epithelial cell lines. Consistently with the higher incorporation of Spike-C3 on the pseudoparticle surface, LV-Luc/Spike-C3 was always more infectious than LV-Luc/Spike, with an infection capacity three to 50 times higher depending on the cell line used (figure 1, SM). For further assay development we selected a combination of LV-Luc/Spike-C3 construct and VeroE6 monkey epithelial kidney cell line that showed the highest ACE2 expression (data not shown). The optimization of key assay parameters is described in SM.

Antibody responses to SARS-CoV-2 Spike appear early after symptoms onset though not in the totality of patients

Using our two newly developed assays we profiled the sera of 162 COVID-19 patients for the SARS-CoV-2 nAb response and for the antibody binding to SARS-CoV-2 Spike domains (S1+S2, S2, RBD) and NP, the Spike S2 of HCoV-OC43 and HCoV-HKU1 and the HA1 protein of the 2009 H1N1 flu virus. Sera were available for 150 patients during the hospital stay, with the sampling occurring between 1-38 days from symptom onset. Early nAb responses showed a large heterogeneity in magnitude (median ID50 1/786, range 1/<40-1/1,660,000) (figure 2A, table S2). nAbs were present in 43.2% patients (19/44, median ID50 1/410) sampled within the first week and in 78.9% (45/57, median ID50 1/1165) within the second week from symptom onset, respectively. Overall, 28.7% (43/150) of patients had no detectable nAbs in their in-hospital sample. IgM and IgA binding to the Spike proteins were more frequently detected than IgG during the first two weeks from symptoms onset (figure 3A). Spike and NP antibodies showed similar frequencies in samples taken 3-4 weeks post-symptom onset. The best binding antibody correlate of nAbs were IgG to any of the Spike antigens used in LIPS (figures 3B-C, S3), Spike IgG thus behaving as a good surrogate marker for nAbs detected in our neutralization assay.

• Download figure
• Open in new tab

Figure 2: Kinetics of the anti-Spike antibody response.

Scatterplots of each patient anti-Spike neutralizing, S1+S2 IgG, RDB IgG, S2 IgG antibodies over time from symptoms onset. Antibody levels correspond to the reciprocal of the ID50 for nAbs or to arbitrary units for all other reactivities. Sampling during hospital attendance (ER or ward) or at post discharge outpatient follow-up visits is shown by the indicated color code. Shown is the moving average of data + SE (black curve line + grey band) as obtained by a LOESS curve fitting polynomial regression.

• Download figure
• Open in new tab

Figure 3: Anti-SARS-CoV-2 Spike neutralizing and binding antibody profile.

(A) Indicated is the percent of 150 COVID-19 patients tested at the in-hospital visit, that had IgG, IgM and IgA to SARS-CoV-2 antigens detected with LIPS, when sampled during the first or second two weeks from symptoms onset. (B) Sera of COVID-19 patients, collected at the indicated timepoints from symptoms onset, were measured by LV based-neutralization assay and the LIPS indicated in grey labels above each row/column. Boxes under the diagonal show each correlation plot of the reciprocal of ID50 and arbitrary units after log10 conversion. Dots correspond to individual measurements, the black line represents the regression line and the grey area its 95%CI. Boxes on the diagonal show as histograms the distribution of values in each assay. Boxes above the diagonal show the corresponding Pearson correlation analysis coefficients. (C) Correlation matrix of the indicated variables in week 1-2. For each pair, the Pearson’s correlation coefficient is shown as number and on a color scale. Statistically non-significant correlations are crossed.

Kinetics and persistence of antibodies to SARS-CoV-2

The longitudinal follow-up showed that at the first out-patient’s visit (median 42 days from symptoms onset, range 22-90), nAbs were still rising in 71.6% of the 87 patients sampled (median ID50 1/3190; range 1/<40-161,000). While at the second visit (median 99 days, range 62-138) nAbs declined in all 77 tested patients (median ID50 1/909, range 1/<40-28,000) (figure 2A, table S2), with a complete loss of nAbs in just three patients. Forty-six patients attended additional visits at or beyond 6 months (median 204 days, range 145-250). In these patients nAb titers were further decreasing (median ID50 1/660, range 1/<40-10,900), but no additional patient lost the nAb response. In 26 non-hospitalized patients, despite a less severe disease, the profile of nAbs and anti-Spike antibodies was similar to that of hospitalized patients (figure S8, SM). Overall, 67.3% (101/150) COVID-19 patients developed nAbs rapidly within 2 weeks from symptoms onset, which persisted up to 36 weeks in all but three patients. As expected, IgM and IgA to SARS-CoV-2 antigens, measured up to eight weeks from symptoms onset, progressively declined during follow-up (figures 3B-C). The kinetic of IgG response to Spike proteins reflected that of nAbs (figure 2, table S2): antibodies to S1+S2 reached a peak by 5-8 weeks and then declined, while those to RBD and S2 continued to rise throughout follow-up, but still correlated significantly with nAbs (figures 3, S3).

Development of neutralizing antibody after symptoms onset correlates with viral control

Prevention of a critical COVID-19 illness is a major hurdle and biomarkers are strongly needed to drive the choice of therapeutic interventions. We performed an extensive analysis of antibody responses and clinical and laboratory parameters collected at or in close proximity of the in-hospital sampling in relation to time to a negative RT-PCR result of the naso-pharyngeal swab and to patient’s survival. In the univariate analysis the presence of nAbs was the only other positive strong predictor of time to a negative swab test (HR 2.238; 95%IC 1.343-3.734) besides IgA to SARS-CoV-2 S1+S2 (HR 1.958; 95%IC 1.079-3.554) (figure S4). Early development of nAbs significantly correlated with the time to a negative swab (p=0.002), i.e. clearance of the virus, when stratified for time from symptoms onset (figure 4A). It was instead impossible to investigate the correlation with viral load at disease onset since a quantitative RT-PCR assay was not yet available when swabs were analysed.

• Download figure
• Open in new tab

Figure 4: Early development of the nAb response correlates with viral control and survival.

Cox regression survival estimates for 150 patients with COVID-19 sampled for nAb response to SARS-CoV-2 during in-hospital visit. The analysis was adjusted for sex and age and stratified for the time from symptoms onset at serum sampling. In (A) the time to a SARS-CoV-2 negative naso-pharyngeal swab (HR 2.238, 95%CI 1.342-3.734; p=0.002) and in (B) the survival rate (HR 2.918, 95%CI 1.321-6.449; p=0.008) was estimated by the presence or absence of a nAb response. Dots represent the Hazard Ratio (HR), filled dots stand for p<0.05.

Lack of a neutralizing antibody response predicts fatal outcome

If developed early after infection, nAbs may limit viral spread, and consequent disease progression. In the 134 hospitalized patients, nAbs detected at the time of the in-hospital sampling did not show any impact on the hospitalization length (table S3), while significantly correlated with critical illness (figure S4). Importantly, lack of a nAb response early after infection was a strong predictor of death when stratified for time from symptoms and corrected for age and sex (HR 2.918, 95%CI 1.321-6.449; p=0.008) (figure 4B). This correlation was still maintained if we applied more stringent ID75 (HR=2.67 (1.2-5.9), p=0.015). In addition, the correlation was further maintained when corrected for each one of the identified correlates of death, including co-morbidities and relevant immune-inflammatory markers, and the absence of IgA to S1+S2 (figure S5).

Kinetics and persistence of neutralizing antibodies is preserved despite advanced age and co-morbidities

We investigated also the impact of advanced age and diverse co-morbidities on nAb response’ kinetics (table S3). In patients above 63 years of age or presenting one or more co-morbidities and who passed away, we detected low or no nAbs in the first weeks after symptoms onset (figure 5). Patients without an early nAb response were significantly older with debilitating co-morbidities, including cancer or chronic pulmonary and kidney diseases. Noteworthy, these patients presented frequently a disease onset with less severe COVID-related respiratory symptoms that did not require ICU admission, and clinical laboratory tests mostly showing a lower immune-inflammatory activation with organ involvement. Conversely, in patients who recovered, advanced age and presence of co-morbidities did not impact on the distribution of early antibody response and, analogously, titre, kinetics and persistence of nAbs after recovery were not affected by either parameter.

• Download figure
• Open in new tab

Figure 5: Development and kinetics of the nAb response according to age or co-morbidities.

Raincloud plot of each patient’s nAb response (circles) expressed as the reciprocal of the ID50 titer. Patients are stratified by time from symptoms onset at sampling (vertical panels, weeks) and clinical outcome (recovered or deceased). Patients are further stratified as below or above the median age of the overall study population (<63 years = blue, >63 years = red) or according to the presence of any co-morbidity (present = red, absent = blue). Shown are the probability density estimate (with the half violin plot upscaled to maximum width for better visualization) and box plots displaying median, IQR, and whiskers extending to 1.96 times the IQR.

Antibody responses to seasonal coronaviruses are temporary boosted without worsening disease progression

Pre-existing antibody responses to other beta-coronaviruses have been proposed to potentially have either a detrimental or beneficial role in COVID-19.^21,22 Testing of IgG to S2 of HCoV-OC43 and -HKU1 in samples collected during the first weeks from symptoms onset did not correlate with either time to a negative swab test or death (figure S4). However, in the same time window, IgG titers to S2 of HKU1 and OC43 correlated with SARS-CoV-2 nAb titers (figures 6A, S6). Interestingly, patients who developed nAbs to SARS-CoV-2 during the first three weeks from symptoms onset had significantly higher IgG titers to either HCoVs compared to patients with undetectable nAbs, a difference that persisted throughout follow-up (figures 6B-C). Conversely, a pre-existing or ongoing Flu infection as documented by an antibody (IgM and/or IgG) response to the H1N1 flu virus HA antigen in the in-hospital samples did not correlate with presence of SARS-CoV-2 nAbs nor survival (figure 3B, table S2), further indicating that the immune response was not compromised in general.

• Download figure
• Open in new tab

Figure 6: NAbs and antibody (IgG) to S2 HCOV-OC43 and HKU1 and SARS-CoV-2.

Sera of COVID-19 patients, collected at the indicated timepoint from symptoms onset, were measured by LV based-neutralization assay and the LIPS to SARS-CoV-2 and HCoV S2 Spike antigen as indicated. (A) Boxes under the diagonal show each correlation plot of the reciprocal of the ID50 and arbitrary units after log1p transformation. Dots correspond to individual measurements, the black line represents the regression line and the grey area its 95%CI. Boxes on the diagonal show as histograms the distribution of values in each assay. Boxes above the diagonal show the corresponding Pearson correlation analysis coefficients. (B) Shown are box plot displaying median of each antibody response as indicated, IQR, and whiskers extending to 1.96 times the IQR, stratified by sampling at the indicated week from symptoms onset and a negative or positive nAb response. (C) Development and kinetics of nAb responses to SARS-CoV-2 during follow-up of patients with negative or positive nAb score at the in-hospital sampling. Each coloured dot corresponds to the reciprocal of the ID50 of a serum of a given infected individual stratified for low, medium or high IgG to HCoV S2 antigens. Shown is the moving average of data + SE (black curve line + grey band) as obtained by a LOESS curve fitting polynomial regression.